A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas cancer and leukemia group B study 7851 (Q44167071)

From Wikidata

Jump to navigation Jump to search

scientific article published on November 1, 1990

Language	Label	Description	Also known as
English	A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas cancer and leukemia group B study 7851	scientific article published on November 1, 1990

Statements

scholarly article

1 reference

Europe PubMed Central

30 November 2017

A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas cancer and leukemia group B study 7851 (English)

reason for preferred rank

most precise value

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

A randomized comparison of methotrexate dose and the addition of bleomycin to CHOP therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas. Cancer and Leukemia Group B study 7851 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

1 reference

based on heuristic

inferred from title

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Clara D. Bloomfield

4

object named as

Bloomfield CD

1 reference

Europe PubMed Central

30 November 2017

author name string

A. J. Gottlieb

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

J. R. Anderson

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

S. J. Ginsberg

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

L. Norton

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

M. Barcos

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

B. A. Peterson

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

N. Nissen

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

E. S. Henderson

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

J. F. Holland

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699653

2 November 2022

language of work or name

0 references

publication date

1 November 1990

1 reference

Europe PubMed Central

30 November 2017

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

1 reference

Europe PubMed Central

30 November 2017

66

1 reference

Europe PubMed Central

30 November 2017

9

1 reference

Europe PubMed Central

30 November 2017

1888-1896

1 reference

Europe PubMed Central

30 November 2017

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2819901101%2966%3A9%3C1888%3A%3AAID-CNCR2820660906%3E3.0.CO%3B2-K

21 January 2018

Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma.A southwest oncology group study

2

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen

3

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study No. 7804

5

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

British Journal of Cancer

9

35

author name string

Peto

publication date

1977

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

High-dose methotrexate: a critical reappraisal

13

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer

14

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

High-dose methotrexate-leucovorin rescue therapy: selected application in non-Hodgkin's lymphoma

16

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity

17

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)

19

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD

20

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Cancer chemotherapy reports

21

6

author name string

Djerassi

publication date

1975

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience

22

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD

24

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma

25

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Chemical modifiers of cancer treatment

26

1 reference

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

https://api.crossref.org/works/10.1002/1097-0142(19901101)66:9%3C1888::AID-CNCR2820660906%3E3.0.CO;2-K

2 November 2022

Identifiers

10.1002/1097-0142(19901101)66:9<1888::AID-CNCR2820660906>3.0.CO;2-K

1 reference

Europe PubMed Central

30 November 2017

1 reference

Europe PubMed Central

30 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44167071&oldid=1762680367"